Welcome to our dedicated page for ACLARION SEC filings (Ticker: ACONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclarion, Inc. filings document material events and governance for a commercial-stage healthcare technology issuer with Nasdaq-listed common stock and warrants. Recent Form 8-K reports cover capital actions such as a share repurchase authorization, executive finance leadership transition, employment agreement terms and Regulation FD communications.
The company's regulatory record also includes annual meeting and stockholder-vote disclosures, director elections, emerging growth company status and common stock information. These filings frame Aclarion's public reporting around its healthcare technology business, governance controls, officer appointments and capital-structure actions.
Bond Ryan reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Strategy Officer Ryan Bond received an equity grant of 55,000 restricted stock units on 6/11/2026 under the company’s equity incentive plan. Each RSU equals one share of common stock and 100% of the award is scheduled to vest on 6/1/2027, with full acceleration upon a qualifying change of control.
Bond Ryan reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Strategy Officer Ryan Bond received an equity grant of 55,000 restricted stock units on 6/11/2026 under the company’s equity incentive plan. Each RSU equals one share of common stock and 100% of the award is scheduled to vest on 6/1/2027, with full acceleration upon a qualifying change of control.
Sequira Amanda Mae reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Amanda Mae Sequira received an award of 20,000 restricted stock units (RSUs) of common stock on 6/11/2026 under the company’s equity incentive plan. Each RSU represents the right to receive one Aclarion share if vesting conditions are met.
The filing states that 100% of these RSUs will vest on 6/1/2027. Any RSUs still unvested at that time will also fully vest if a change of control, as defined in the equity incentive plan, occurs before then. After this grant, Sequira directly holds 20,000 shares/RSUs.
Sequira Amanda Mae reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Amanda Mae Sequira received an award of 20,000 restricted stock units (RSUs) of common stock on 6/11/2026 under the company’s equity incentive plan. Each RSU represents the right to receive one Aclarion share if vesting conditions are met.
The filing states that 100% of these RSUs will vest on 6/1/2027. Any RSUs still unvested at that time will also fully vest if a change of control, as defined in the equity incentive plan, occurs before then. After this grant, Sequira directly holds 20,000 shares/RSUs.
Breidbart Scott reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Scott Breidbart received an equity grant in the form of restricted stock units. He was awarded 20,000 RSUs on 6/11/2026 under the company’s equity incentive plan, with each unit representing one share of ACON common stock.
All of these RSUs are scheduled to vest on 6/1/2027, meaning he will receive the underlying shares at that time if conditions are met. Any unvested RSUs will fully vest earlier if there is a change of control as defined in the plan. Following this award, Breidbart directly holds 25,664 shares.
Breidbart Scott reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Scott Breidbart received an equity grant in the form of restricted stock units. He was awarded 20,000 RSUs on 6/11/2026 under the company’s equity incentive plan, with each unit representing one share of ACON common stock.
All of these RSUs are scheduled to vest on 6/1/2027, meaning he will receive the underlying shares at that time if conditions are met. Any unvested RSUs will fully vest earlier if there is a change of control as defined in the plan. Following this award, Breidbart directly holds 25,664 shares.
Gould Gregory A reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Financial Officer Gregory A. Gould received an equity compensation grant in the form of restricted stock units. On 6/11/2026 he was awarded 50,000 RSUs, each representing a contingent right to receive one share of Aclarion common stock.
All 50,000 RSUs are scheduled to vest on 6/1/2027, meaning the shares will be delivered if he remains eligible through that date. Any outstanding and unvested RSUs will also fully vest if a change of control occurs as defined in the company’s equity incentive plan. Following this grant, Gould holds 50,000 shares directly reported in this filing.
Gould Gregory A reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Financial Officer Gregory A. Gould received an equity compensation grant in the form of restricted stock units. On 6/11/2026 he was awarded 50,000 RSUs, each representing a contingent right to receive one share of Aclarion common stock.
All 50,000 RSUs are scheduled to vest on 6/1/2027, meaning the shares will be delivered if he remains eligible through that date. Any outstanding and unvested RSUs will also fully vest if a change of control occurs as defined in the company’s equity incentive plan. Following this grant, Gould holds 50,000 shares directly reported in this filing.
Ness Brent reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Executive Officer Brent Ness received an equity award in the form of 100,000 restricted stock units (RSUs) on June 11, 2026 under the company’s equity incentive plan. Each RSU represents a right to receive one share of ACON common stock.
The Form 4 shows the RSUs at a grant price of $0.00 per unit, reflecting a compensation award rather than a market purchase. All of the RSUs are scheduled to vest on June 1, 2027, and any unvested RSUs will fully vest if a change of control occurs as defined in the plan. Following this grant, Ness is shown holding 106,300 common shares directly.
Ness Brent reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Chief Executive Officer Brent Ness received an equity award in the form of 100,000 restricted stock units (RSUs) on June 11, 2026 under the company’s equity incentive plan. Each RSU represents a right to receive one share of ACON common stock.
The Form 4 shows the RSUs at a grant price of $0.00 per unit, reflecting a compensation award rather than a market purchase. All of the RSUs are scheduled to vest on June 1, 2027, and any unvested RSUs will fully vest if a change of control occurs as defined in the plan. Following this grant, Ness is shown holding 106,300 common shares directly.
Wesemann William reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director William Wesemann received an equity award of 20,000 restricted stock units. The RSUs were granted on 6/11/2026 under the company’s equity incentive plan and each unit represents one share of ACON common stock. All RSUs are scheduled to vest on 6/1/2027, with any unvested units fully vesting if a change of control occurs. Following this grant, Wesemann directly holds 21,563 shares of common stock.
Wesemann William reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director William Wesemann received an equity award of 20,000 restricted stock units. The RSUs were granted on 6/11/2026 under the company’s equity incentive plan and each unit represents one share of ACON common stock. All RSUs are scheduled to vest on 6/1/2027, with any unvested units fully vesting if a change of control occurs. Following this grant, Wesemann directly holds 21,563 shares of common stock.
Thramann Jeffrey John reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Executive Chairman Jeffrey John Thramann received a grant of 100,000 restricted stock units (RSUs) of common stock. Each RSU represents a contingent right to receive one share of Aclarion common stock.
All of the RSUs are scheduled to vest on June 1, 2027, and any outstanding unvested RSUs will fully vest if a change of control occurs as defined under the company’s equity incentive plan. Following this grant, Thramann holds 100,000 shares/RSUs directly.
Thramann Jeffrey John reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. reported that Executive Chairman Jeffrey John Thramann received a grant of 100,000 restricted stock units (RSUs) of common stock. Each RSU represents a contingent right to receive one share of Aclarion common stock.
All of the RSUs are scheduled to vest on June 1, 2027, and any outstanding unvested RSUs will fully vest if a change of control occurs as defined under the company’s equity incentive plan. Following this grant, Thramann holds 100,000 shares/RSUs directly.
Neal David K reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Neal David K reported an equity compensation grant. He received 20,000 restricted stock units (RSUs) on 6/11/2026 under the company’s equity incentive plan, each representing one future share of common stock. Following this award, he now holds 22,502 shares of common stock directly.
The filing notes that 100% of the RSUs vest on 6/1/2027, meaning he must remain eligible through that date to receive the underlying shares. Any unvested RSUs will also fully vest if there is a change of control as defined in the company’s equity incentive plan.
Neal David K reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Neal David K reported an equity compensation grant. He received 20,000 restricted stock units (RSUs) on 6/11/2026 under the company’s equity incentive plan, each representing one future share of common stock. Following this award, he now holds 22,502 shares of common stock directly.
The filing notes that 100% of the RSUs vest on 6/1/2027, meaning he must remain eligible through that date to receive the underlying shares. Any unvested RSUs will also fully vest if there is a change of control as defined in the company’s equity incentive plan.
Deitsch Stephen reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Stephen Deitsch received an equity grant of 20,000 restricted stock units (RSUs). The award was granted on 6/11/2026 under Aclarion's equity incentive plan at no cash cost per unit, with each RSU representing the right to receive one share of common stock.
According to the terms, 100% of the RSUs will vest on 6/1/2027, and any unvested RSUs will fully vest if there is a change of control as defined in the company’s equity incentive plan. Following this grant, Deitsch holds 20,000 shares/units directly.
Deitsch Stephen reported acquisition or exercise transactions in this Form 4 filing.
Aclarion, Inc. director Stephen Deitsch received an equity grant of 20,000 restricted stock units (RSUs). The award was granted on 6/11/2026 under Aclarion's equity incentive plan at no cash cost per unit, with each RSU representing the right to receive one share of common stock.
According to the terms, 100% of the RSUs will vest on 6/1/2027, and any unvested RSUs will fully vest if there is a change of control as defined in the company’s equity incentive plan. Following this grant, Deitsch holds 20,000 shares/units directly.
Aclarion, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected seven directors to serve until the 2027 annual meeting, with each nominee receiving more votes for than withheld.
Stockholders also ratified the appointment of Haynie & Company as the company’s independent registered public accounting firm, with 1,588,388 votes for, 20,623 against, and 10,985 abstaining. In addition, an amendment to Aclarion’s 2022 equity incentive plan was approved, receiving 453,431 votes for, 323,512 against, 1,302 abstentions, and 841,751 broker non-votes.
Aclarion, Inc. reported the results of its 2026 annual meeting of stockholders. Stockholders elected seven directors to serve until the 2027 annual meeting, with each nominee receiving more votes for than withheld.
Stockholders also ratified the appointment of Haynie & Company as the company’s independent registered public accounting firm, with 1,588,388 votes for, 20,623 against, and 10,985 abstaining. In addition, an amendment to Aclarion’s 2022 equity incentive plan was approved, receiving 453,431 votes for, 323,512 against, 1,302 abstentions, and 841,751 broker non-votes.